We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Red Blood Cell Folate Level Is a Biomarker for Risk of Neural Tube Defects

By LabMedica International staff writers
Posted on 13 Aug 2014
The importance of maintaining high red blood cell (RBC) levels of folate during pregnancy to reduce risk of neural tube defects was confirmed in a review of results obtained by a large study of expectant mothers in China.

A team of American and Chinese researchers worked with results obtained from 247,831 participants in a prospective community intervention project in China (1993–1995) that was designed to prevent neural tube defects with 400 micrograms/day folic acid supplementation. More...
An additional 1194 participants came from a population based randomized trial (2003–2005) designed to evaluate the effect of folic acid supplementation on blood folate concentration among Chinese women of reproductive age.

Results revealed that the risk of neural tube defects was high at the lowest estimated RBC folate concentrations (for example, 25.4 neural tube defects per 10,000 births at 500 nanomoles/L) and decreased as estimated RBC folate concentration increased. Risk of neural tube defects was substantially reduced at estimated RBC folate concentrations above 1,000 nanomoles/L (for example, six neural tube defects per 10,000 births at 1,180 nanomoles/L).

The data derived from the Chinese studies was consistent with the existing literature on the link between folate and neural tube defects. Furthermore, neural tube defect risk estimates developed using the proposed model and population level RBC information were consistent with the prevalence of neural tube defects in the American population before and after food fortification with folic acid. Therefore, the authors concluded that RBC folate concentrations, as a biomarker for risk of neural tube defects, could be used to facilitate evaluation of prevention programs as well as to identify subpopulations at elevated risk for a neural tube defect affected pregnancy due to folate insufficiency.

The study, which was carried out by investigators at the [US] Centers for Disease Control and Prevention (Atlanta, GA, USA) and Peking University, Beijing, China), was published in the July 29, 2014, online edition of the British Medical Journal.

Related Links:
Centers for Disease Control and Prevention
Peking University


Gold Member
Quality Control Material
iPLEX Pro Exome QC Panel
POC Helicobacter Pylori Test Kit
Hepy Urease Test
Sperm Quality Analyis Kit
QwikCheck Beads Precision and Linearity Kit
New
Gold Member
Clinical Drug Testing Panel
DOA Urine MultiPlex
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Immunology

view channel
Image: Original illustration showing how exposure-linked mutation patterns may influence tumor immune visibility (Photo courtesy of Máté Manczinger, HUN-REN Szeged BRC)

Cancer Mutation ‘Fingerprints’ to Improve Prediction of Immunotherapy Response

Cancer cells accumulate thousands of genetic mutations, but not all mutations affect tumors in the same way. Some make cancer cells more visible to the immune system, while others allow tumors to evade... Read more

Industry

view channel
Image: MG Tech adds STOMmics Stereo-seq spatial multi-omics technology to its potfolio (photo courtesy of STOmics)

MGI Tech Strengthens Sequencing Portfolio with Dual Acquisition

MGI Tech Co., Ltd. (Shenzhen, China) announced the acquisition of STOmics and CycloneSEQ on March 3, 2026, as part of its “SEQALL+GLI+Omics” strategy. According to the company, the combined portfolio spans... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.